Clonmel Healthcare has launched Bosutinib Clonmel 100mg and 500mg film-coated tablets. Bosutinib Clonmel is indicated for the treatment of adult patients with:
Newly diagnosed chronic phase (CP) Philadelphia chromosome — positive myelogenous leukaemia (PH+CML); and
CP, accelerated phase (AP), and blast phase (BP) Ph +CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Full prescribing information is available on request or alternatively please go to clonmel-health.ie. Medicinal product subject to restricted medical prescription. Further information is available via Clonmel Healthcare on 01 620 4000. PA 126/369/1-3.
